Shots: The NDA is based on two P-III studies of surufatinib in patients with pancreatic and extra-pancreatic NET in China. The anticipated PDUFA date is April 30, 2022 The same […]readmore
Tags : Surufatinib
Shots: Chi-Med initiated the filing of NDA to the US FDA for surufatinib to treat pancreatic & non-pancreatic NET & plans to complete the NDA submission in the H1’21 The […]readmore
Shots: The two companies collaborated to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib and fruquintinib, with BeiGene’s tislelizumab against multiple solid tumor cancer indications in the US, EU, […]readmore
Shots: The US FDA has granted FT designation to Chi-Med’s surufatinib for the treatment of both advanced and progressive pancreatic NET and non-pancreatic NET in patients who are not amenable […]readmore